FIELD: medicine.
SUBSTANCE: invention relates to the application of 5-((2-(4-(1-(2- hydroxyethyl)piperidine-4-il)benzamide)pyridine-4-yl)oxy)-6-(2-methoxyethoxy)-N-methyl-1H-indole-1-carboxamide or its pharmacologically acceptable sesquicuccinate salt as a therapeutic agent for the treatment of hepatocellular carcinoma.
EFFECT: disclosed is possibility of application 5-((2-(4-(1-(2- hydroxyethyl)piperidine-4-il)benzamide)pyridine-4-yl)oxy)-6-(2-methoxyethoxy)-N-methyl-1H-indole-1-carboxamide for the treatment of hepatocellular carcinoma.
4 cl, 1 dwg, 4 tbl, 4 ex
| Title | Year | Author | Number |
|---|---|---|---|
| THERAPEUTIC AGENT FOR TREATING BREAST CANCER | 2016 |
|
RU2730503C2 |
| THERAPEUTIC AGENT FOR BILIARY TRACT CANCER TREATMENT | 2016 |
|
RU2728932C2 |
| PHARMACEUTICAL COMPOSITION FOR TREATING A TUMOUR | 2018 |
|
RU2750539C2 |
| THERAPEUTIC AGENT FOR BILE DUCT CANCER | 2016 |
|
RU2712222C2 |
| ANTITUMOUR THERAPEUTIC AGENT | 2016 |
|
RU2718048C2 |
| COMBINATION THERAPIES FOR TREATMENT OF HEPATOCELLULAR CARCINOMA | 2019 |
|
RU2787993C2 |
| MACROCYCLIC COMPOUND AND ITS USE | 2018 |
|
RU2783238C2 |
| COMBINED THERAPY WITH EZH2 INHIBITOR | 2018 |
|
RU2754131C1 |
| ANTITUMOR AGENT AND ANTITUMOR EFFECT AMPLIFIER | 2018 |
|
RU2783759C2 |
| USE OF EP4 RECEPTOR ANTAGONISTS FOR TREATMENT OF NASH-ASSOCIATED LIVER CANCER | 2017 |
|
RU2717331C2 |
